Forget Weight Loss Drugs: Here’s Another Reason to Buy Eli Lilly Stock
Eli Lilly (LLY -0.30%) brought in $19.8 billion in revenue in the first quarter of 2026, and most of it can be traced back to the medicines everyone has heard of by now: tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity. Its weight loss medicines, and the ones behind them in the pipeline, will likely carry the top line for years, though leadership in that market is never guaranteed. But that didn’t stop […]
Read more